StemCyte, Inc. Licenses Promising IP for Stem Cell Therapy to Treat Stroke
Published: Nov 30, 2009
COVINA, Calif., Nov. 30 /PRNewswire/ -- StemCyte, Inc. concluded an exclusive license and commercialization agreement with Academia Sinica, the National Laboratory of Taiwan, for certain proprietary methods and Intellectual Property (IP) related to the treatment of Chronic Stroke with stem cells. This method and IP was pioneered by a team led by Professor John Lin, MD, PhD and members of Academia Sinica. Professor Lin is currently the exclusive collaborator with StemCyte on this indication and method.
"We are delighted to be working with Professor Lin and his team on this critical and broad medical indication," said Ken Giacin, StemCyte's CEO. "Stroke affects millions of people every year throughout the world and can be a debilitating disorder. Securing this agreement with Academia Sinica coupled with related IP that StemCyte owns will allow us to pursue the clinical and potential commercial application of Adult stem cells to treat this disorder."
StemCyte has the most racially diverse collection of life-giving cell units derived from umbilical cord blood in the world and has successfully developed the leading such bank in Taiwan. With over 1,000 successful transplants using their units worldwide, StemCyte has focused on leveraging its proven publicly banked units to enhance regenerative bio-therapies for major indications affecting blood, nerve, brain and sensitive tissue cells. This exclusive agreement for the IP and commercial method to potentially treat chronic stroke is in addition to the other patent protected methods of optimal cell collection, storage and treatment.
About Professor John Lin, MD PhD
Shinn-Zong Lin, M.D., Ph.D. (John Lin), Professor of Neurosurgery of China Medical University Hospital and Vice Superintendent, Center for Neuropsychiatry, is the principal investigator for the chronic stroke indication and methods of treatment under Academia Sinica in Taiwan. He is a distinguished expert in neuroscience and neurosurgery contributing to more than 150 reviewed papers, delivering over 150 presentations to specialists and receiving 25 honors around the globe since 1980. His research findings and publications have been referenced by experts in the field.
CONTACT: Calvin Cole, Vice President, North America, +1-512-422-2700,
Web site: http://www.StemCyte.com/